NCT06481566

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chongqing University Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if first-line Almonertinib plus upfront stereotactic ablative body radiotherapy (SABR) works to treat EGFR-mutated advanced non-small cell lung cancer. The main questions it aims to answer are: Does first-line Almonertinib plus upfront stereotactic ablative body radiotherapy to residual primary lung lesions prolong the progression-free survival of EGFR-mutated advanced non-small cell lung cancer. Participants will: Take first-line Almonertinib for 2-4 months, then deliver SABR to residual primary lung lesions, after that go on Almonertinib maintenance treatment； Visit the hospital once every 3 months for checkups and tests； Keep a diary of their symptoms ；

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	stereotactic ablative body radiotherapy	The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.

Timeline

• Start date: 2024-06-21
• Primary completion: 2026-01-01
• Completion: 2026-06-30
• First posted: 2024-07-01
• Last updated: 2024-09-04

Locations

1 site across 1 country: China